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Abstract
Hyponatraemia is common, affecting about one in five
of all hospitalized patients. Minor degrees of chronic hy-
ponatraemia cause cognitive and motor impairment, and
severe hyponatraemia is associated with substantial mor-
bidityandmortality.Syndromeofinappropriateantidiuretic
hormonesecretion(SIADH)isacommoncauseofhypona-
traemia and is often poorly understood and inappropriately
treated. Clinical evaluation and simple biochemical assess-
ment should guide management. The introduction of vaso-
pressinantagonists,orvaptans,intoclinicalpracticeheralds
the beginning of a new and exciting era for this important
group of disorders.
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Introduction
Hyponatraemia, defined as an excess of water in relation
to sodium in the extracellular fluid, is the most common
electrolyte disorder in hospitalized patients [1]. It is usu-
ally mild and relatively asymptomatic, but acute severe hy-
ponatraemia can cause substantial morbidity and mortality
[2]. In addition, overly rapid correction of chronic hypona-
traemia can cause severe neurologic defects and even death
[3]. Hyponatraemia is, therefore, important to appreciate,
both because of its potential morbidity and because it can
be a marker of serious underlying disease. Evidence is now
emergingthatevenminordegreesofchronichyponatraemia
are associated with significant motor and cognitive impair-
ment [4].
Hyponatraemia (serum sodium <135 mmol/l) occurs in
15–22%ofhospitalizedpatients[5].Theincidenceofmod-
erate and severe hyponatraemia is lower occurring in 1–7%
of hospitalized patients [5]. It is known that severe hypona-
traemia is actually acquired in hospital in approximately
half of those who develop a serum sodium <125 mmol/l
[1]. Certain populations are at increased risk, including the
elderly, especially nursing home residents [2].
This common disorder remains incompletely understood
and often inappropriately managed because of its associ-
ation with a myriad of underlying disease states, and its
multiple aetiologies with different pathophysiologic mech-
anisms [5]. It is likely that the underlying disorders divert
attention from hyponatraemia. It can be difficult to know to
what extent symptoms and morbidity are caused as a direct
result of the hyponatraemia, the underlying conditions or
a combination of both. In particular, in hospital-acquired
hyponatraemia, which is frequently multi-factorial, there
appears to be a low recognition of deteriorating hypona-
traemia resulting in inadequate or delayed management.
Movig et al. [6] reviewed the discharge diagnosis of ‘hy-
ponatraemia’in2632casesandidentifiedalowrecognition
rate, with only 30% of patients with severe hyponatraemia
accurately classified. Hoorn et al. [7] have suggested that
better management may be achieved by physician educa-
tion and development of preventative hospital systems. The
development of evaluation and treatment strategies for hy-
ponatraemiamusttakeintoaccounttheheterogeneityofthe
condition and the marked differences in symptomatology
and clinical outcomes based on the acuteness or chronicity
of the hyponatraemia.
The articles in this supplement begin to address this ed-
ucational gap. Despite the areas of uncertainty in man-
agement, clinicians should not overlook this very common
condition. Knowledge of the syndrome of inappropriate
antidiuretic hormone (SIADH), risk factors for develop-
ment and the underlying mechanisms is essential for all
physicians [3]. Conventional therapy for hyponatraemia is
limited, but the introduction of vasopressin-receptor antag-
onists offers the possibility of an effective method to treat
hyponatraemia, by virtue of their unique aquaretic effect
to selectively increase solute-free water excretion by the
kidneys [3].
Clinical evaluation of hyponatraemia
Serum sodium concentration is the main determinant of
plasma osmolality, and most hyponatraemic states are char-
acterized by elevated plasma levels of arginine vasopressin
(AVP) [5]. SIADH is the most frequent cause of hypona-
traemia, although hyponatraemia associated with volume
depletion of the extracellular fluid also occurs commonly.
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The clinical assessment of the patients’ extracellular fluid
(ECF) volume status coupled with a history and examina-
tion to identify potential drug-related hyponatraemia and
underlying predisposing conditions often permits a suffi-
cient categorization of the underlying aetiology to allow
initial treatment and to inform the plan for further diag-
nostic evaluation [3]. The three major classifications of
hypotonic hyponatraemia are based on the patients’ ECF
volume status: hypovolaemic hyponatraemia, euvolaemic
hyponatraemia and hypervolaemic hyponatraemia.
When the origin of the hyponatraemia is not obvious, the
possibility of pseudohyponatraemia should be considered.
Marked elevation of either lipids or proteins in plasma can
cause artificial decrease in serum sodium because of the
larger relative proportion of plasma volume that is then
occupied by the excess lipids or proteins. In such cases,
directly measured plasma osmolality will be normal [8].
Hyponatraemia with normal or even raised osmolality
can also occur when high levels of other non-cell perme-
ant solutes are present in the plasma. In most instances,
these situations should not lead to diagnostic confusion be-
causethecauseisobvious.Thissituationismostcommonly
seenwithhyperglycaemiawhentheaccompanyingglucose-
induced osmotic diuresis can result in hypertonicity despite
hyponatraemia[9].Radiocontrastagents,manitol,sorbitol,
glycerol, maltose and glycine also act as osmotic agents
that withdraw water from the intracellular compartment
[10]. Glycine infusion into the bladder or uterus during
transurethral resection of the prostate (TURP) or endo-
scopic uterine surgery can lead to absorption of a large
volume of fluid with resultant hyponatraemia and devel-
opment of the ‘post-TURP syndrome’ [11]. Clinical mani-
festations include headache, mental depression, visual dis-
turbance, blindness, seizures, cardio respiratory arrest and
death and are probably attributable to the direct toxicity of
the absorbed glycine and its metabolites.
However, in most clinical situations hyponatraemia is
accompanied by significant hypo-osmolality indicating ex-
cess water relative to solute/sodium in the ECF compart-
ment [5]. This can be produced either by excess body wa-
ter, resulting in a dilution of remaining body solute, or by
depletion of body solute/sodium relative to body water.
This segregation into dilutional (euvolaemic and hyper-
volaemic) or depletional (hypovolaemic) is a conceptu-
ally useful paradigm to the understanding of the under-
lying mechanisms and pathogenesis of hyponatraemia [3].
In reality, many hyponatraemic states involve components
of both solute depletion and water retention but the bal-
ance should determine the appropriate therapy in particular
clinical situations.
Patients with clinical signs of volume depletion (e.g. or-
thostatic drop in blood pressure, tachycardia) should be
considered hypovolaemic and those with evidence of vol-
ume expansion (oedema or ascites) hypervolaemic, unless
there are alternative explanations for these findings.
Theclinicalsettingandotherlaboratorycluestothepres-
ence of volume depletion, such as raised urea or creatinine,
may provide corroboration. When the clinical assessment
is equivocal, a trial of volume expansion can be helpful in
establishing the type of hyponatraemia, and will be ther-
apeutic if volume depletion is the cause of the hypona-
Table 1. Aetiologies of depletional (hypovolaemic) hyponatraemia
Renal loss of sodium with water retention Extrarenal loss of sodium
with water retention
• Diuretic therapy • Gastrointestinal losses
• Cerebral salt wasting (a) Vomiting
• Mineralocorticoid deficiency (b) Diarrhoea
(a) Autoimmune • Third space losses
(i) Adrenal only (a) Bowel obstruction
(ii) Polyglandular endocrinopathy (b) Pancreatitis
(b) Adrenal haemorrhage (c) Muscle trauma
(i) Meningococcaemia (b) Burns
(ii) Idiopathic • Sweat losses
(c) Infection (a) Endurance exercise
(i) Tuberculosis
(ii) Fungus
(iii) CMV
(d) Adrenal enzyme deficiencies
(congenital adrenal hyperplasia)
• Salt-wasting nephropathy
• Bicarbonaturia, glucosuria, ketonuria
CMV = cytomegalovirus.
Reprinted from [3], with permission from Elsevier.
traemia. After a 0.5–1 l infusion of isotonic (0.9%) NaCl,
patients with hypovolaemic hyponatraemia will begin to
correct their hyponatraemia without developing signs of
volume overload [5]. Conversely, in patients with SIADH
the serum sodium will remain unchanged or decrease.
Aspoturinesodiumconcentrationcanbeausefuladjunct
to categorizing the ECF volume status. If the patient is vol-
umedepleted,his/herurinesodiumconcentrationshouldbe
<30 mmol/l unless the kidney is the site of the sodium loss.
In those with euvolaemic hyponatraemia, the urine sodium
level is usually ≥30 mmol/l unless they have become sec-
ondarily sodium depleted. In states of volume expansion
with decreased effective arterial blood volume e.g. heart
failure, cirrhosis, renal failure or nephrotic syndrome, the
spot urine is usually low (<30 mmol/l) [3]. The concomi-
tant use of diuretics can of course make interpretation of
urinary sodium measurements difficult.
Thereareawholerangeofconditionsthatcancauseeach
of the three types of hypotonic hyponatraemia (see Tables 1
and 2) [3]. Investigation and medium- to long-term treat-
ment can be planned using this classification. Adopting
such a systematic approach to clinical evaluation will help
address some of the deficiencies in care that previous stud-
ies have highlighted [3,5].
Management challenges in SIADH
In contrast to hyponatraemia secondary to volume deple-
tion, which is usually corrected by treatment of the un-
derlying condition and intravenous fluids, the management
of dilutional hyponatraemia remains a challenge in many
clinical settings [3,5]. The only definitive treatment of
SIADH is elimination of its underlying cause. Most cases
caused by curable malignant disease resolve with effective
antineoplastic therapy, and most of those due to med-
ication resolve promptly when the offending agent is
discontinued [5] However, in many instances, includingSIADH and hyponatraemia: foreword iii3
Table 2. Aetiologies of dilutional (euvolaemic and hypervolaemic) hyponatraemia
Impaired renal free water excretion
• Euvolaemic
(a) SIADH
(i) Tumours
– Pulmonary/mediastinal (bronchogenic carcinoma, mesothelioma, thymoma)
– Nonchest (duodenal carcinoma, pancreatic carcinoma, ureteral/prostate carcinoma, uterine carcinoma, nasopharyngeal carcinoma,
leukaemia)
(ii) CNS disorders
– Mass lesions (tumours, brain abscesses, subdural haematoma)
– Inflammatory diseases (encephalitis, meningitis, systemic lupus, acute intermittent porphyria, multiple sclerosis)
– Degenerative/demyelinative diseases (Guillain–Barr´ e syndrome; spinal cord lesions)
– Miscellaneous (subarachnoid haemorrhage, head trauma, acute psychosis, delirium tremens, pituitary stalk section, transphenoidal
adenomectomy, hydrocephalus)
(iii) Drug induced
– Stimulated AVP release (nicotine, phenothiazines, tricyclics)
– Direct renal effects and/or potentiation of AVP antidiuretic effects (DDAVP, oxytocin, prostaglandin synthesis inhibitors)
– Mixed or uncertain actions (ACE inhibitors, carbamazepine and oxcarbazepine, chlorpropamide, clofibrate; clozapine,
cyclophosphamide, 3,4-methylenedioxymethamphetamine [“Ecstasy”], omeprazole; serotonin reuptake inhibitors, vincristine)
(iv) Pulmonary diseases
– Infections (tuberculosis, acute bacterial and viral pneumonia, aspergillosis, empyema)
– Mechanical/ventilatory (acute respiratory failure, COPD, positive pressure ventilation)
(v) Other
–A I D Sa n dA R C
– Prolonged strenuous exercise (marathon, triathalon, ultramarathon, hot-weather hiking)
– Senile atrophy
– Idiopathic
(b) Glucocorticoid deficiency
(c) Hypothyroidism
(d) Decreased urinary solute excretion
(i) Beer potomania
(ii) Very low protein diet
• Hypervolaemic
(a) CHF
(b) Cirrhosis
(c) Nephrotic syndrome
(d) Renal failure
(i) Acute
(ii) Chronic
Excessive water intake
• Primary polydipsia
• Dilute infant formula
• Freshwater drowning
ACE = angiotensin-converting enzyme; AIDS = acquired immune deficiency syndrome; ARC = AIDS-related complex; AVP = arginine vasopressin;
CHF = congestive heart failure; CNS = central nervous system; COPD = chronic obstructive pulmonary disease; DDAVP = desmopressin acetate;
SIADH = syndrome of inappropriate antidiuretic hormone secretion.
Reprinted from [3], with permission from Elsevier.
malignancy, the underlying condition is chronic, hypona-
traemia has been present for an indeterminate duration and
there may be varying degrees of mild neurological symp-
tomatology. The cases presented by Lubbe et al. [12] and
the review of treatment options by Zietse et al. [13] in
the accompanying articles in this supplement outline the
current treatment strategies and identify some of the areas
of uncertainty in the management of SIADH. Currently,
treatment failures are common in this group of patients.
In the elderly, physicians generally tolerate the presence of
mild hyponatraemia if water restriction does not result in
normalization of serum sodium. Unfortunately, there are
few randomized controlled trials to guide therapy, but the
concept of asymptomatic hyponatraemia has recently been
challenged by epidemiological evidence from a number of
studies in Europe and the USA [14,15]. Decaux reported
a series of 122 consecutive patients hospitalized with mild
hyponatraemia, ∼21% of whom were admitted with falls
[15]. After controlling for age, sex and other known risk
factors for falls, the adjusted odds ratio for falls in patients
withhyponatraemiawas67,comparedwithacontrolgroup.
The same authors have demonstrated that clinically asymp-
tomatic patients with chronic hyponatraemia have attention
deficits and gait abnormalities that were clinically unrec-
ognized by the patients and their physicians [4]. Arieff and
Ayus [16] reported pre-operative hyponatraemia in 7.2% of
patients with hip factures.
Hyponatraemia has also been associated with negative
outcomes in many chronic diseases, most notably in pa-
tients with congestive cardiac failure [3]. One study of 161
patients with severe congestive heart failure found hypona-
traemia to be a significant predictor of cardiovascular mor-
tality, with 69% of hyponatraemic patients dying within
24 months compared with 40% of patients without base-
line hyponatraemia (P < 0.001) [17]. Similarly, in a study
examining admission hyponatraemia among 4123 geriatric
patients,in-hospitalmortalitywasfoundtobe16%amongst
patients with admission hyponatraemia versus 8% amongstiii4 D. O’Donoghue and A. Trehan
those without this condition [18]. In the general adult hos-
pitalized population, Anderson et al. found that mortality
rates were 60-fold higher in patients with even asymp-
tomatic hyponatraemia compared to normonatraemic pa-
tients [19]. The degree to which this strong association
between hyponatraemia and negative outcomes is causally
related to the hyponatraemia and might be improved with
more effective therapies is not known.
Hospitalization figures relating to hyponatraemia in
Europearenotaccuratelyknown;however,dataintheUSA
show that there are ∼1 million hospitalizations per year
with a principal or secondary discharge diagnosis of hy-
ponatraemia [20], as well as an estimated 105000–120000
annual emergency room visits and 1.4–3.4 million annual
office visits for hyponatraemia. The direct cost for treating
hyponatraemia in the USA on an annual basis was esti-
mated to range between $1.6 billion and $3.6 billion. The
majority,∼70%,oftheadditionalcostswereinthosewhose
hospitalization was prolonged due to hyponatraemia [20].
Next steps
Vasopressin-receptor antagonists have long been antic-
ipated as an effective method to treat hyponatraemia
by virtue of their unique effect to selectively increase
solute-free water excretion by the kidneys. A range of
studies have shown that these agents correct and main-
tain serum sodium levels in patients with hypervolaemic
and euvolaemic hyponatraemia in the long and short term
[21–23]. Information regarding these studies is discussed
in Professor Zietse’s paper ‘Current and future treatment
options in SIADH’ later in this supplement [13].
The vaptans (for vasopressin antagonists) herald the be-
ginning of a new and exciting era in the management of
hyponatraemia and have rekindled interest in this impor-
tant group of disorders. There is no need for therapeutic
nihilism in the management of hyponatraemia. Our use of
these agents and the optimal place for conventional therapy
needstobeguidedbyasystematicapproachtoclinicaleval-
uationandanexistingknowledgeofthepathophysiologyof
hyponatraemia informed by the results of well-constructed
clinical trials to examine the impact of these agents on pa-
tient experience, clinical outcomes and costs of health care
delivery [3].
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